Loading stock data…
Oric Pharmaceuticals, Inc. (ORIC)
$12.62-0.24 (-1.87%)
Market ClosedLast close Sep 8
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
ORIC Pharmaceuticals, Inc. in the Healthcare sector is trading at $12.62 with a market capitalization of $1.3B. Wall Street consensus targets $20.67 (12 analysts), implying a +63.8% move over the next 12 months. The stock is currently 15% below its 52-week high of $14.93, remaining 18.4% above its 200-day moving average. On fundamentals, Piotroski 3/9 flags weak fundamentals, Altman Z in the safe zone. The Whystock Score of 90/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +63.8% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (USD) | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 |
|---|---|---|---|---|---|
| Total Revenue | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | — | — | — | — | — |
| Operating Income | -$45.30M↓ | -$39.62M↓ | -$34.55M↑ | -$36.67M↑ | -$39.06M |
| Net Income | -$41.49M↓ | -$35.77M↓ | -$30.50M↑ | -$32.59M↑ | -$36.35M |
Peer Comparison
JNJUNHPFE
Fundamentals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies to counter the resistance mechanisms in cancers in the United States. Its clinical stage product candidates include enozerti...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$1.31B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.99
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-36.81%
Volume
Today's trading volume
954,763
Recent News
Is ORIC Pharmaceuticals' (ORIC) Equity-Funded ESOP Masking or Clarifying Its Widening Net Losses?
In early August 2026, ORIC Pharmaceuticals reported second-quarter and first-half results showing a wider net loss of US$41.49 million and US$77.26 million respectively, but a narrower basic loss per share from continuing operations compared with a year earlier. Just days before, the company also filed a US$12.41 million shelf registration for 1,100,000 common shares under an ESOP-related offering, highlighting ongoing use of equity-based incentives alongside its loss-making operations. We...
Companies Like ORIC Pharmaceuticals (NASDAQ:ORIC) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
A Look At ORIC Pharmaceuticals (ORIC) Valuation After Promising Rinzimetostat Phase 1b Prostate Cancer Data
ORIC Pharmaceuticals (ORIC) updated investors on Phase 1b data for rinzimetostat plus darolutamide in metastatic castration resistant prostate cancer, and selected a 400 mg daily dose for a planned global Phase 3 trial. See our latest analysis for ORIC Pharmaceuticals. The latest rinzimetostat update comes after a sharp 1 day share price return of 18.93% to US$8.89, following a 27.07% 7 day share price decline. The 1 year total shareholder return of 93.68% points to strong but volatile...
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
Shares of Immunovant, Alto and Oric Pharmaceuticals fell this week on clinical trial updates. Elsewhere, Orca Bio’s cell therapy hit a delay and Korsana entered a reverse merger.
ORIC Pharmaceuticals (ORIC) Is Down 36.1% After Advancing Lower-Toxicity Prostate Cancer Drug to Phase 3
In late March 2026, ORIC Pharmaceuticals reported Phase 1b data showing that rinzimetostat 400 mg once daily plus darolutamide in post-abiraterone metastatic castration-resistant prostate cancer achieved strong early radiographic progression-free survival with mostly mild side effects, and selected this dose for the planned global Phase 3 Himalayas-1 trial. A key insight is that rinzimetostat’s exposure–response analysis suggested similar efficacy at 400 mg and 600 mg but meaningfully lower...